A phase IB proof-of-concept, antiviral activity, safety, and pharmacokinetics study of GS-1720
Latest Information Update: 19 Apr 2024
At a glance
- Drugs GS 1720 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Proof of concept
Most Recent Events
- 06 Mar 2024 Results (n=7) assessing antiviral activity, safety, and pharmacokinetics of GS-1720 in the first cohort dosed with 450 mg, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 05 Mar 2024 Results published in the Gilead Sciences Media Release.
- 05 Mar 2024 According to a Gilead Sciences media release, data from this trial were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024).